THERAPY DOSSIER · th-fe1affed3e3d

3,6'-dithiopomalidomide (DP) and pomalidomide (Pom)

Drug · Cereblon (CRBN) modulator / immunomodulatory imide (IMiD).

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Cereblon (CRBN) modulator / immunomodulatory imide (IMiD).
Target: CHEMBL3833061 (Cereblon)
Injury models: TBI
Reported indication: Not recorded
First approval: 2013
Development stage: Not recorded
ChEMBL record: CHEMBL43452 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Pomalyst; Imnovid; CC-4047; 3,6'-dithiopomalidomide (analog)
Note: Not recorded

Clinical trials 12

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06956170 ↗PHASE3active not recruiting

Belantamab mafodotin + pomalidomide + dexamethasone vs PVd in RRMM (DREAMM 8)

Multiple Myeloma

Enrolment: 21 · Results not recorded

NCT04925193 ↗PHASE2active not recruiting

Personalized Selinexor-based Therapy (incl Pomalidomide) in R/R Multiple Myeloma

Multiple Myeloma

Enrolment: 18 · Results not recorded

NCT05348213 ↗PHASE2recruiting

Novel Targeted Drugs incl Pomalidomide + R-ICE in R/R DLBCL

Diffuse Large B Cell Lymphoma

Enrolment: 76 · Results not recorded

NCT03520985 ↗PHASE2terminated

Alternate day dosing of pomalidomide in refractory multiple myeloma

Refractory Multiple Myeloma

Enrolment: 34 · Results not recorded

NCT02578121 ↗PHASE2withdrawn

Ixazomib, pomalidomide and dexamethasone in relapsed multiple myeloma

Multiple Myeloma

Enrolment: 0 · Results not recorded

NCT01135199 ↗PHASE2withdrawn

Pomalidomide for refractory cough in idiopathic pulmonary fibrosis

Pulmonary Fibrosis

Enrolment: 0 · Results not recorded

NCT00833833 ↗PHASE1/PHASE2completed

CC-4047 alone or with low-dose dexamethasone in relapsed/refractory multiple myeloma

Multiple Myeloma

Enrolment: 259 · Results not recorded

NCT02343042 ↗PHASE1/PHASE2recruiting

Selinexor with backbone treatments including pomalidomide in RRMM/NDMM

Multiple Myeloma

Enrolment: 300 · Results not recorded

NCT01754402 ↗PHASE1/PHASE2unknown

Bendamustine + pomalidomide + dexamethasone in relapsed/refractory MM

Multiple Myeloma

Enrolment: 56 · Results not recorded

NCT01421186 ↗PHASE1/PHASE2completed

MOR03087 (anti-CD38) mono and with pomalidomide/lenalidomide in RRMM

Multiple Myeloma

Enrolment: 91 · Results not recorded

NCT02431208 ↗PHASE1completed

Atezolizumab +/- IMiD/Daratumumab (incl Pomalidomide) in Multiple Myeloma

Multiple Myeloma

Enrolment: 85 · Results not recorded

NCT01522547 ↗PHASE1completed

Dose-escalation study of CC-4047 (pomalidomide) and fetal haemoglobin induction in sickle cell disease

Anemia, Sickle Cell

Enrolment: 12 · Results not recorded

Preclinical evidence 2

2 studies reported at therapy level; 2 evidence entries itemised.

PMID 32589144 ↗2020Reported benefit

3,6'-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation.

RatTBIControlled cortical impactSprague-DawleyMalen = n = 5 per group for contusion volume, behaviour, Fluoro-Jad…IntravenousDP 0.1 and 0.5 mg/kg; pomalidomide 0.1 and 0.5 mg/kg5 h post-injury (primary); a 7 h post-injury arm was also tested and was ineffe…

Model: Moderate controlled cortical impact, 5 mm craniotomy over left parietal cortex, 5 mm rounded tip at 4 m/s to 2 mm below dura

A single intravenous dose at 5 h post-injury reduced contusion volume from 19.0 +/- 0.74 per cent (vehicle) to 12.9 +/- 0.22 and 7.4 +/- 0.87 per cent with DP 0.1 and 0.5 mg/kg, improved all four behavioural tests, preserved NeuN positive neurons, reduced degenerating neurons by 64.9 to 65.6 per ce…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.93. Machine-extracted fields require source verification.

PMID 27353053 ↗2016Reported benefit

Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat.

RatTBIControlled cortical impactSprague-DawleyMaleIntravenous0.5 mg/kg or 0.1 mg/kg5 hours or 7 hours after injury

Model: Moderate to severe controlled cortical impact traumatic brain injury

Pomalidomide 0.5 mg/kg given 5 hours after injury significantly reduced injury volume and functional impairment, neurodegeneration, neuronal apoptosis and cytokine induction. The same dose at 7 hours, and 0.1 mg/kg at 5 hours, were not effective. In vitro, pomalidomide dose-dependently reduced glut…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…